References
- World Health OrganizationGlobal Hepatitis Report2017 Available from: https://www.who.int/hepatitis/publications/global-hepatitis-report2017/en/April2017Accessed March 26, 2019
- McMahonBJThe natural history of chronic hepatitis B virus infectionSemin Liver Dis200424Suppl 1172115192797
- LaiCLRatziuVYuenM-FPoynardTViral hepatitis BLancet200336294012089209414697813
- FattovichGNatural history and prognosis of hepatitis BSemin Liver Dis20032314758
- European Association for the Study of the LiverEASL clinical practice guidelines: management of chronic hepatitis B virus infectionJ Hepatol20125716718522436845
- LimSGAmarapurkarDNChanHLReimbursement policies in the Asia-Pacific for chronic hepatitis BHepatol Int201591435125788378
- ShengYJLiuJYTongSWLamivudine plus adefovir combination therapy versus entecavir monotherapy for lamivudine-resistant chronic hepatitis B: a systematic review and meta-analysisVirol J20118139321824397
- LinZLuXLiuCClinical effects comparison of lamivudine combined with adefovir dipivoxil or entecavir alone on HBV-related hepatocirrhosis in 3 yearsPharmacy Today20151168176
- WooHYChoiJYYoonSKRescue therapy with adefovir in decompensated liver cirrhosis patients with lamivudine-resistant hepatitis B virusClin Mol Hepatol201420216817625032183
- WuSKongYPiaoHOn-treatment changes of liver stiffness at week 26 could predict 2-year clinical outcomes in HBV-related compensated cirrhosisLiver Int20183861045105429119705
- WaiCTGreensonJKFontanaRJA simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis CHepatology200338251852612883497
- JayakumarRJoshiYSinghSLaboratory evaluation of three regimens of treatment of chronic hepatitis B: tenofovir, entecavir and combination of lamivudine and adefovirJ Lab Physicians20124101622923916
- WangLCChenEQCaoJDe novo combination of lamivudine and adefovir versus entecavir monotherapy for the treatment of naïve HBeAg-negative chronic hepatitis B patientsHepatol Int20115267167621484140
- LiuFWangXWeiFEfficacy and resistance in de novo combination lamivudine and adefovir dipivoxil therapy versus entecavir monotherapy for the treatment-naive patients with chronic hepatitis B: a meta-analysisVirol J20141115924673792
- CaiSYuTJiangYComparison of entecavir monotherapy and de novo lamivudine and adefovir combination therapy in HBeAg-positive chronic hepatitis B with high viral load: 48-week resultClin Exp Med201616342943626164128
- DuQWDingJGSunQFCombination lamivudine and adefovir versus entecavir for the treatment of naive chronic hepatitis B patients: a pilot studyMed Sci Monit20131975175624019010
- JiaJTangHNingQReal-world evidence for nucleoside/nucleotide analogues in a 5-year multicentre study of antiviral-naive chronic hepatitis B patients in China: 52-week resultsAntivir Ther2017233201209
- Sheppard-LawSZablotska-ManosIKermeenMFactors associated with HBV virological breakthroughAntivir Ther2016221536027631160
- LiuYMillerMDKitrinosKMTenofovir alafenamide demonstrates broad cross-genotype activity against wild-type HBV clinical isolates and maintains susceptibility to drug-resistant HBV isolates in vitroAntiviral Res2017139253128017761
- ChangTTLiawYFWuSSLong-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis BHepatology201052388689320683932
- LiawYFSungJJChowWCLamivudine for patients with chronic hepatitis B and advanced liver diseaseN Engl J Med2004351151521153115470215
- LiangXEDaiLYangSLCombining routine markers improves the accuracy of transient elastography for hepatitis B cirrhosis detectionDig Liver Dis201648551251826965782
- LeeHSKimJKCheongJYPrediction of compensated liver cirrhosis by ultrasonography and routine blood tests in patients with chronic viral hepatitisKorean J Hepatol201016436937521415580
- PapatheodoridisGVManolakopoulosSEASL clinical practice guidelines on the management of chronic hepatitis B: the need for liver biopsyJ Hepatol200951122622719410321